24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LEUPOLIEVA DEPOT 3.75 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LEUPOLIEVA DEPOT 3.75 MG |
|---|---|
| Composition | Leuprolide Acetate Depot for Injection 3.75 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | 1 Vial & 1 x 2mL Ampoule |
| Country of Origin | India |
LEUPOLIEVA DEPOT 3.75 MG (Leuprolide Acetate Depot for Injection 3.75 mg) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LEUPOLIEVA DEPOT 3.75 MG (Leuprolide Acetate Depot for Injection 3.75 mg) is a prescription hormonal medicine containing Leuprolide Acetate 3.75 mg in a long-acting depot formulation. Leuprolide belongs to the Gonadotropin-Releasing Hormone (GnRH) Agonist class and is used to suppress the production of sex hormones.
When administered continuously, Leuprolide initially stimulates the pituitary gland and subsequently reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a significant reduction in testosterone production in males and estrogen production in females.
LEUPOLIEVA DEPOT 3.75 MG may be used in the management of advanced prostate cancer, endometriosis, uterine fibroids, and other approved hormone-dependent conditions, depending on the patient's clinical condition and the prescribing information applicable to the product.
The depot formulation is designed to provide sustained release of Leuprolide Acetate, helping maintain hormonal suppression over the prescribed treatment interval.
The injection should be prepared and administered by a qualified healthcare professional.
LEUPOLIEVA DEPOT 3.75 MG is commonly used for:
Patients receiving Leuprolide therapy require regular monitoring of treatment response and relevant clinical parameters.
LEUPOLIEVA DEPOT 3.75 MG is used for conditions where suppression of sex hormone production provides therapeutic benefit.
Leuprolide is widely used as androgen deprivation therapy (ADT) for advanced prostate cancer. By reducing testosterone levels, it helps slow the growth of hormone-sensitive prostate cancer cells.
Leuprolide can reduce estrogen stimulation and help manage pain and other symptoms associated with endometriosis.
It may be prescribed in selected patients to temporarily reduce estrogen levels and help decrease the size of uterine fibroids.
The medicine may be used when temporary suppression of gonadal hormone production is clinically required.
For prostate cancer, Leuprolide may be used alongside other medicines as determined by the treating oncologist.
Leuprolide belongs to the GnRH Agonist class.
LEUPOLIEVA DEPOT works by:
In prostate cancer, reduced testosterone levels can help slow the growth of androgen-dependent cancer cells.
Like all medicines, LEUPOLIEVA DEPOT 3.75 MG may cause side effects. Their severity and frequency vary between patients.
Sudden feelings of warmth and sweating are frequently reported.
Pain, redness, swelling, or discomfort may occur around the injection site.
Tiredness and weakness may occur during treatment.
Some patients may experience headaches.
Reduced sexual desire may occur due to hormonal suppression.
Men undergoing androgen deprivation therapy may experience erectile difficulties.
Changes in mood or emotional well-being may occur.
Long-term hormonal suppression can contribute to reduced bone mineral density.
Changes in body weight or body composition may occur during prolonged treatment.
Seek immediate medical attention if you experience:
Patients should promptly report severe or unusual symptoms to their healthcare provider.
The dosage and administration schedule of LEUPOLIEVA DEPOT 3.75 MG should be determined by a qualified healthcare professional according to the specific indication and approved product information.
The 3.75 mg depot formulation is designed for extended-duration treatment, with the exact administration interval depending on the indication and product-specific prescribing information.
Treatment schedules differ depending on whether the medicine is being used for prostate cancer, endometriosis, uterine fibroids, or another approved indication.
Clinical response and degree of hormonal suppression may influence ongoing treatment.
Individual patient factors may affect treatment planning.
Other hormonal or anticancer medicines may be used alongside Leuprolide when clinically appropriate.
Before starting treatment, inform your doctor if you have:
Depending on the indication, patients may require:
Inform your healthcare professional about all prescription medicines, supplements, vitamins, and herbal products you are taking.
At the beginning of Leuprolide treatment, testosterone levels can temporarily increase before they decline. This is called tumor flare.
In some patients with advanced prostate cancer, tumor flare may temporarily worsen symptoms such as:
A healthcare professional may prescribe additional treatment to reduce the risk or effects of tumor flare when clinically appropriate.
It is commonly used for advanced prostate cancer and may also be prescribed for conditions such as endometriosis and uterine fibroids, depending on the approved indication.
Leuprolide Acetate is a GnRH agonist that suppresses sex hormone production when administered continuously.
No. Leuprolide is a hormonal therapy, rather than a traditional cytotoxic chemotherapy medicine.
It lowers testosterone production, thereby reducing hormonal stimulation of hormone-sensitive prostate cancer cells.
Tumor flare is a temporary increase in certain prostate cancer symptoms that can occur because testosterone initially rises after starting GnRH agonist therapy.
Yes. Long-term hormonal suppression may reduce bone mineral density, so bone health may need to be monitored.
Yes. Hot flashes are a common effect of hormonal suppression.
Yes. The depot injection should be prepared and administered by a qualified healthcare professional according to the prescribed treatment schedule.